Healthcare professionals
Medical Information
Medical information is the channel through which healthcare professionals, pharmacists, hospital and institutional purchasers and the regulatory staff of our distributors obtain accurate, sourced answers about Ergopharm products. It exists to state what is true of the product — its composition, its characteristics, how it behaves and how it is packed — and to say plainly where the answer is not ours to give. Responses are drawn from our own development, analytical and stability records, from the approved product information, and from the pharmacopoeial monographs the product complies with. Nothing sent from this channel is promotional, and no response should be read as a recommendation to prescribe.
What this channel can and cannot answer
- Composition and excipients
- In scope. Qualitative and quantitative composition, the oil carrier and co-solvent used in an ampoule presentation, and the excipient profile of an oral solid, including the presence or absence of a specified excipient.
- Physicochemical characteristics
- In scope. Appearance, pH where applicable, viscosity of oil solutions, solubility behaviour, and the pharmacopoeial monograph the substance complies with.
- Storage, transport and excursions
- In scope. The labelled storage statement, the basis for it, and how a reported temperature excursion is assessed against our stability data. Assessment of a specific excursion requires the batch number and the full time-and-temperature record.
- Stability and shelf life
- In scope. Shelf life as labelled, the study design behind it, and in-use or post-opening limits where they have been established.
- Compatibility and handling
- In scope. Container-closure and administration-set compatibility, behaviour of oil solutions at low temperature, filtration and warming guidance, and known incompatibilities we have data on. Where we have no data, we will say so rather than extrapolate.
- Pack, carton and serialisation details
- In scope. Pack sizes, presentation, carton and leaflet contents, GS1 data carried in the DataMatrix, and how a serialised pack is verified. Suspected falsified packs go to the quality channel, not here.
- Documentation for a specific batch
- In scope for our partners. Certificate of analysis, batch-specific data and shipping documentation, released to the consignee of that batch or to a competent authority, on identification of the batch.
- Individual treatment decisions
- Out of scope. Whether to start, continue, adjust, combine or stop treatment in a particular patient is a clinical judgement for the treating prescriber, who has the history, the examination and the responsibility. We will not make that judgement at a distance and we will not appear to.
- Dosing for an individual patient
- Out of scope. We can state what the approved product information says; we cannot translate it into a dose, an interval or a course for a named patient.
- Diagnosis and monitoring
- Out of scope. We do not interpret laboratory results, imaging or clinical findings, and we do not advise on monitoring schedules for an individual.
- Off-label and non-medical use
- Out of scope. We do not provide guidance supporting use outside the approved indications, and we decline enquiries seeking dosing, cycling or clearance information for non-medical use. See our responsible-use statement.
- Comparison with other manufacturers' products
- Out of scope. We speak for our own products and our own data.
How to ask, and what to expect
- 01
1 — Identify yourself and your setting
Give your name, professional role, institution or company, and country. This channel is for healthcare professionals and for the regulatory and quality staff of licensed partners. It is not a patient service, and enquiries from members of the public seeking advice on their own treatment will be redirected to their prescriber or pharmacist.
- 02
2 — Identify the product precisely
State the product name and strength as printed on the carton, and the monograph number where you have it. If the enquiry concerns a specific pack, add the batch (LOT) number, the expiry, and the verification code from the serialisation panel. An enquiry that names only an active substance can only be answered in general terms.
- 03
3 — State the question and the context
Say what you need to know and why, in your own words. If a specific event prompted the enquiry — an excursion, an appearance change, a compatibility problem during preparation — give the sequence, the dates, the conditions and any measurements. Attach photographs of the pack and the serialisation panel where appearance or labelling is at issue.
- 04
4 — Acknowledgement within one working day
Every enquiry is logged with a reference and acknowledged within one working day of receipt. The acknowledgement states who is handling it and what, if anything, we still need from you.
- 05
5 — Standard response within three working days
A question answerable from approved product information, the pharmacopoeial monograph or our published data is answered in writing within three working days, with the source of each statement identified.
- 06
6 — Ten working days where records must be retrieved
Enquiries requiring retrieval of batch manufacturing or analytical records, review of stability data, a compatibility assessment or input from the quality unit are answered within ten working days. If it will take longer, we tell you the reason and the expected date rather than letting the enquiry go quiet.
- 07
7 — Safety-related content is escalated immediately
If an enquiry describes a suspected adverse reaction, a lack of expected effect, use in pregnancy or breastfeeding, overdose, misuse, medication error or occupational exposure, it is passed to pharmacovigilance within one working day of receipt, independently of when the technical answer is ready.
Standing statement. Ergopharm does not solicit enquiries about the use of its products. Any request reaching us unsolicited — by email, through this site, at a professional meeting, or through a distributor — is handled as a medical enquiry: it is logged, answered from documented sources, and kept on file. It is not treated as a promotional contact and it does not create a commercial relationship. If an enquiry mentions, in any part of it and however incidentally, a suspected adverse reaction, a suspected lack of effect, misuse, abuse, medication error, occupational exposure, use in pregnancy or breastfeeding, or a suspected quality defect, that information is forwarded to our pharmacovigilance function for assessment and follow-up. Reporting is not optional on our side and does not depend on whether you consider the event related to the product. Personal data in an enquiry is used only to answer it and to meet safety-reporting obligations, and is handled as described in our privacy policy. If you would prefer to report a suspected adverse reaction directly, write to pv@ergopharm.net; a suspected quality defect or falsified pack should go to quality@ergopharm.net. Reporting to us does not replace reporting to your national pharmacovigilance system, and you should do both.